Kristin Abate - 06 Nov 2024 Form 3 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
Chief Accounting Officer
Signature
Nancy Smith, Attorney-in-Fact for Kristin Abate
Issuer symbol
KPTI
Transactions as of
06 Nov 2024
Net transactions value
$0
Form type
3
Filing time
22 Nov 2024, 16:01:57 UTC
Next filing
04 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KPTI Common Stock 140,300 06 Nov 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 87,978 restricted stock units ("RSUs") which were unvested as of November 6, 2024. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.